CTOs on the Move

Daily Cardinal Alumni Association

www.dailycardinal.net

 
Daily Cardinal Alumni Association is a Oak Park, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Baptist East/Milestone Wellness Ctr.

Fitness classes, lap pool, personal training, weight-loss programs, Pilates, weight training and more. Free mini-membership. All ages and fitness levels welcome.

Clemex Technologies

Clemex Technologies Inc. is a Longueuil, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kemberton

Kemberton is a leading provider of technology-enabled revenue cycle management services to hospitals for complex claims. We specialize in the management and collection of workers compensation, motor vehicle accident claims, veteran administration and the resolution of insurance denials for hospitals and physician practice groups. Kemberton helps accelerate collection times and maximize reimbursements for over 300 hospital clients across 35 states, resulting in over $1.5 billion dollars of incremental cash payments for our clients.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.

Igenix

IGeneX Inc. is a Reference Laboratory specializing in State-of-the-Art Clinical and Research Testing for Lyme Disease and Associated Tick-borne Diseases.